Management of Adult Growth Hormone Deficiency
Start GH replacement with low, individualized doses (200-300 mcg/day for ages 30-60 years), titrate every 1-2 months based on IGF-1 levels and side effects, and monitor patients every 1-2 months during titration then every 6 months thereafter. 1
Initiation and Dosing Strategy
Age-Based Starting Doses
The dosing must be stratified by age due to varying susceptibility to side effects and different physiologic requirements 1:
- Ages 30-60 years: Start 200-300 mcg/day
- Age ≥60 years: Start 100-200 mcg/day (lower doses, slower titration due to increased side effect risk)
- Age <30 years: Start 400-500 mcg/day (higher initial doses appropriate)
- Transitioning from pediatric treatment: May require even higher doses than young adults
Dose Titration Protocol
Increase doses by 100-200 mcg every 1-2 months based on three factors 1:
- Clinical response
- Absence of side effects
- IGF-1 levels in age-adjusted reference range (target upper half of range)
Clinical benefits may not manifest for 6 months or longer, so patience during titration is essential 1.
Special Population Adjustments
Women on oral estrogen require substantially higher GH doses because oral estrogen stimulates SOCS2, a postreceptor inhibitor of GH action in the liver, suppressing IGF-1 production 1, 2. Women on transdermal estrogen do not require this dose adjustment. When women discontinue oral estrogen or switch to transdermal preparations, GH doses must be lowered to prevent side effects 1.
Morbid obesity may also necessitate increased dosing 2.
Monitoring Protocol
During Dose Titration
Monitor every 1-2 months with 1:
- Clinical assessment
- Evaluation for adverse effects
- IGF-1 levels (primary monitoring parameter)
After Dose Stabilization
Monitor every 6 months (semiannually) with 1, 2:
- IGF-1 levels (measure 6 weeks after initiating therapy, after dose changes, then every 6 months)
- Body weight, blood pressure, waist circumference, BMI
- Metabolic profile: fasting glucose and lipid panel
- Thyroid and adrenal function (GH can unmask or alter other hormone deficiencies)
- Quality of life assessment
Additional Monitoring
- Bone mineral density by DXA: Every 18 months 2
- Pituitary MRI: Periodically assess residual pituitary mass 2
Critical monitoring caveat: Maintain IGF-1 levels below the upper limit of normal to minimize side effects 2. The commonly used target is the upper half of the age-adjusted reference range 1.
Contraindications and Precautions
Absolute Contraindication
Active malignancy is an absolute contraindication to GH treatment 1. However, reassuringly, multiple studies show no effect of GH replacement on tumor regrowth or recurrence in patients with pituitary tumors or craniopharyngiomas 1.
Diabetes Management
GH treatment in patients with diabetes mellitus may require adjustments in antidiabetic medications 1 because GH is an insulin antagonist. Monitor glucose closely and adjust diabetes medications proactively.
Thyroid and Adrenal Monitoring
Thyroid and adrenal function must be monitored during GH therapy 1 because GH can unmask central hypothyroidism or adrenal insufficiency. These deficiencies should be replaced before or concurrently with GH initiation.
Expected Benefits and Timeline
GH replacement improves 2:
- Body composition: Decreased visceral adipose tissue by 9% in women, increased lean body mass by up to 7% in first year
- Lipid profile: Reduced total and LDL cholesterol, increased HDL cholesterol
- Bone mineral density: Increased bone mass after 12 months, more beneficial in men and those with severe bone loss
- Exercise capacity: Enhanced maximum oxygen uptake and muscle power (sustained for at least 10 years)
- Cardiac function: Increased lean body mass, cardiac stroke volume, and left ventricular mass
- Quality of life: Variable but generally improved
Effects typically manifest within 6 weeks of initiating therapy but may require longer for maximum benefit 2.
Common Side Effects and Management
Side effects occur in approximately 20% of patients at recommended doses and are usually reversible by lowering the GH dose 2. Common side effects include:
- Fluid retention (dose-dependent—this is why low starting doses are preferred)
- Arthralgias, myalgias
- Paresthesias, carpal tunnel syndrome
- Sleep apnea, sleep disturbances
- Dyspnea
If replacement doses are too high, insulin resistance with diabetes may occur 2.
Safety Profile
Long-term surveillance studies demonstrate a favorable safety profile when appropriate replacement doses are used 2. GH administration does not increase the rate of pituitary adenoma recurrence (RR 0.887; 95% CI 0.56-1.33) 2. The development of new cancers and new-onset diabetes remains a theoretical concern, but evidence does not support increased risk with proper dosing.
Clinical Pitfalls to Avoid
- Do not use weight-based dosing—individualized dosing based on age, gender, and estrogen status is superior 1
- Do not start with high doses—this increases fluid retention and other side effects
- Do not forget to adjust doses when women change estrogen formulations (oral to transdermal or vice versa)
- Do not overlook thyroid and adrenal function—these must be optimized before or during GH therapy
- Do not expect immediate results—clinical benefits may take 6+ months to manifest